Document is current
Any future updates will be listed below
-
Authors
Armstrong, Eric
Hemmerling, Anke
Miller, Steve
Huibner, Sanja
Kulikova, Maria
Crawford, Emily
Castañeda, Gloria R.
Coburn, Bryan
Cohen, Craig R.
Kaul, Rupert
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (Studentship, PJT-156123)
National Institutes of Health (HHSN2722013000141, HHSN2722013000141)
- License Information
-
More Information
Article History
Received: 21 October 2023
Accepted: 2 May 2024
First Online: 21 June 2024
Declarations
:
: The LACTIN-V trial (NCT02766023) obtained written consent from all participants before enrolment. Study protocols for the larger trial were approved by the institutional review boards (IRBs) at University of California, San Francisco General Hospital (San Francisco, CA, USA; IRB 15–18143), Stroger Hospital of Cook County (Chicago, IL, USA), University of California San Diego Antiviral Research Center (San Diego, CA, USA; IRB: 160023X), and Washington University Infectious Disease Clinical Research Unit (St Louis, MO, USA). Immunology and microbiology performed at the University of Toronto (Toronto, ON, Canada) were reviewed and approved by the University of Toronto HIV Research Ethics Board (protocol #36947).
: Not applicable.
: CRC – paid consultant for Osel Inc. All other authors declare they have no competing interests.
